1. Home
  2. MP vs PRAX Comparison

MP vs PRAX Comparison

Compare MP & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MP Materials Corp.

MP

MP Materials Corp.

HOLD

Current Price

$41.57

Market Cap

7.4B

ML Signal

HOLD

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$307.33

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MP
PRAX
Founded
2017
2015
Country
United States
United States
Employees
998
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.4B
7.1B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
MP
PRAX
Price
$41.57
$307.33
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
15
Target Price
$75.25
$572.13
AVG Volume (30 Days)
5.3M
323.9K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
12.28
N/A
EPS
N/A
N/A
Revenue
$331,952,000.00
N/A
Revenue This Year
$100.51
N/A
Revenue Next Year
$60.41
$7,758.26
P/E Ratio
N/A
N/A
Revenue Growth
147.15
N/A
52 Week Low
$37.81
$37.25
52 Week High
$100.25
$366.52

Technical Indicators

Market Signals
Indicator
MP
PRAX
Relative Strength Index (RSI) 35.96 46.85
Support Level N/A $284.87
Resistance Level $64.62 $331.51
Average True Range (ATR) 2.54 16.94
MACD -0.24 -2.52
Stochastic Oscillator 27.34 35.57

Price Performance

Historical Comparison
MP
PRAX

About MP MP Materials Corp.

MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America. The company is also developing a rare earth metal, alloy, and magnet manufacturing facility in Fort Worth, Texas. The company's operations are organized into two reportable segments: Materials and Magnetics.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: